AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

SLGL · NASDAQ · Biotechnology

Sol-Gel Technologies

Develops topical dermatology treatments through licensees and a clinical pipeline.

$68.81

After-hours close+0.21 (+0.31%)

At close$68.60(−5.47%)

Something off on this page? Send us feedback.

Profile

Sol-Gel Technologies Ltd.SLGLHealth Care

Develops topical dermatology treatments and has used product-rights sales and licensing. Twyneo and Epsolay are FDA-approved; its current pipeline includes SGT-610 and SGT-210, with commercialization outside the United States handled through licensees.

Develops topical dermatology treatments spanning approved products and investigational programs. Its portfolio pairs prescription treatments with development programs that use topical formulations. Twyneo treats acne, and Epsolay treats inflammatory rosacea lesions; the company sold their U.S. rights to Mayne Pharma while licensees commercialize them in Canada and other territories.

SGT-610 targets the prevention of new basal-cell-carcinoma lesions in people with Gorlin syndrome, and SGT-210 is a topical EGFR-inhibitor platform for unmet-need indications. The business depends on licensee execution and regulatory approvals in licensed territories, while clinical development continues for its investigational programs.

Company facts

CEOMoshe Arkin

ListedFeb 1, 2018

ExchangeNASDAQ

HeadquartersNess Ziona, Israel

CountryIsrael

Employees36

CIK0001684693

ISINIL0011417206

Key statistics

Market cap$224.9M

EPS (ttm)−$5.64

P/E (ttm)−12.20

ROE-44.1%

P/B4.68

P/S125.31

Dividend yield—

Beta0.94vs XLV 0.43

Year to date +62.8% · Average volume (30d) 60.2K

Analysts

Price target, next 12 months$110.00+59.9%Median of 6 analysts · vs the Aug 28 close

ConsensusBuy5 of 6 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $68.81

High$110.00+59.9%

Median$110.00+59.9%

Low$110.00+59.9%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Jul 20, 2026	H.C. Wainwright	Reiterate	Buy	$50	$110
Oct 27, 2025	H.C. Wainwright	Target		$21	$50

Earnings

EPS

Estimate−$2.58

ReportedDue Nov 19, 2026

Revenue

Estimate$100.0K

ReportedDue Nov 19, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 20, 2026Q2 FY26	−$2.36	−$1.13	+52.1%	$75.0K	$591.0K	+688.0%	−0.11%
May 28, 2026Q1 FY26	−$2.86	−$1.31	+54.2%	$900.0K	$108.0K	−88.0%	−1.89%
Mar 19, 2026Q4 FY25	$0.39	−$1.07	−374.4%	$6.5M	$6.5M	0.0%	−10.70%
Nov 20, 2025Q3 FY25	−$2.09	−$2.13	−1.9%	$6.5M	$400.0K	−93.8%	+2.52%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$1.0M	$17.3M	$400.0K	$696.0K	$108.0K	$591.0K
Gross profit	$1.0M	$17.3M	$400.0K	$696.0K	$108.0K	$591.0K
Operating income	−$9.1M	$11.2M	−$6.3M	−$3.4M	−$3.9M	−$4.2M
Net income	−$8.8M	$11.6M	−$5.9M	−$3.0M	−$3.7M	−$3.7M
Diluted EPS	−$0.32	$4.17	−$2.13	−$1.07	−$1.31	−$1.13
Gross margin	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Operating margin	-879.6%	65.1%	-1,572.0%	-490.1%	-3,569.4%	-704.2%

Fiscal years (4-quarter sums)FY21 $31.3M · FY22 $3.9M · FY23 $2.0M · FY24 $11.5M · FY25 $19.4M

Revenue by product · FY25

License$18.6M · 96%

Royalty$707.0K · 4%

Service, Other$82.0K · 0%

Revenue by geography · FY25

United States$16.7M · 86%

Canada$1.7M · 9%

Switzerland$711.0K · 4%

Segment Geographical Groups Of Countries Group Five$278.0K · 1%

China$27.0K · 0%

Balance sheet, Jun 30, 2026Cash & short-term investments $47.9M · Total debt $770.0K · Total assets $53.8M · Shareholders' equity $48.1M

Dividends

No dividends on record.

Ownership

Institutions 38.36%1.25M sharesInsiders 53.71%1.76M sharesOther 7.93%259.2K shares

Shares outstanding 3.27M · Float 853.0K · 26.1% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Moshe Arkin · director, 10 percent owner, officer: Chairman of Board and CEO	1.75M	53.54%	Form 4	Mar 18, 2026
Opaleye Management Inc. · 10 percent owner	494.9K	15.14%	Form 4	Aug 14, 2026
Great Point Partners LLC	274.4K	8.39%	13F	May 15, 2026
Phoenix Holdings Ltd.	210.8K	6.45%	13F	May 11, 2026
Trails Edge Capital Partners, LP	85.5K	2.62%	13F	May 15, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 12, 2026	Opaleye Management Inc.	10 percent owner	+951	$71.50
Jul 13, 2026	Opaleye Management Inc.	10 percent owner	+775	$73.89
Jul 14, 2026	Opaleye Management Inc.	10 percent owner	+920	$73.43
Jul 8, 2026	Opaleye Management Inc.	10 percent owner	+300	$73.69
Jul 10, 2026	Opaleye Management Inc.	10 percent owner	+229	$73.95